ARGC Arion Group Corporation (CE)

Artepharm Global Corp. (OTCBB: ARGC) (www.artepharmglobal.com) reports that at the 5th Pan-African malaria conference, held in Nairobi in early November 2009, it was announced that malaria has been eliminated on the East Africa Comoros island of Moheli, with a population of 36,000. This was done with the aid of a comprehensive Chinese-assisted Artequick® treatment program that was administered and run by Artepharm Global's partner - Artepharm Co., a modern PRC China-based pharmaceutical company and as reported by Reuters...

In a laboratory in China's southern city of Guangzhou, scientists are enhancing the rare sweet wormwood shrub, from which artemisinin -- the best drug to fight malaria -- is derived. Artepharm Co.'s intent is to improve and use the drug patented as Artequick, as a uniquely Chinese weapon to fight malaria in Africa, where it still kills one child every 30 seconds. The Chinese-backed eradication program on the island of Moheli has proven to be a huge success. Professor Li Guoqiao of Artepharm Co., is spearheading the project on Moheli, which belongs to the Comoros group of islands at the northern mouth of the Mozambique Channel. In mid-November 2007, he launched a "mass drug administration" exercise on the island. Its entire population of 36,000 had to take two courses of anti-malarial drugs to flush the parasite from their bodies -- on day one and on day 40. The rationale was that while mosquitoes pass the parasite from person to person, they are merely "vectors" and not hosts. The real reservoir of the disease is people, and many carry the malaria parasite in their bodies without even showing symptoms.

"The key is to eradicate the source, which is in people. Without the source, the vectors are harmless," said Li Guoqiao. "The results were startling. While the parasite carrier rate in Moheli ranged from 5 to 94 percent from village to village before the exercise, that fell to 1 percent or less from January 2008 and has stayed around that figure since. "Before, 70 to 80 percent of hospital patients were being treated for malaria. After that, you hardly find any," Li said. Comoros now bars anyone from entering Moheli unless they take a course of Artequick, the antimalarial drug, which is a mix of artemisinin, primaquine and pyrimethamine. The Comoros government has asked Beijing to roll out the same program in two of its larger islands, Grande Comore and Anjouan, with a total population of 760,000. Li said Beijing supported the idea in principle and that funding is being worked out.

See Dateline News Video of Artepharm's success in Moheli on the Company's web site www.artepharmglobal.com.

About Artepharm Global

Artepharm Global has acquired the patent and worldwide marketing rights for Artequick®, a natural artemisinin-based anti-malaria drug developed by Artepharm Co. Artepharm Co. is a modern pharmaceutical company involved in R&D and the manufacturing of artemisinin-based anti-malarias and anti-viral traditional Chinese medicines. It was jointly established by a group of experts specializing in the research of Qinghao, commonly known as Artemisia annua. For more information got to www.artepharmglobal.com.

Safe Harbour Statements

Except for the statements of historical fact contained herein, the information presented in this news release constitutes "forward-looking statements" as such term is used in applicable United States and Canadian laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans, "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved) are not statements of historical fact and should be viewed as "forward-looking statements". Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the actual results of exploration activities, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labour disputes and other risks of the mining industry including, without limitation, those associated with the environment, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, title disputes or claims limitations on insurance coverage. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.

Forward looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. Such forward-looking statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, including, the risks and uncertainties outlined in our most recent financial statements and reports and registration statement filed with the United States Securities and Exchange Commission (the "SEC") (available at www.sec.gov) and with Canadian securities administrators (available at www.sedar.com). Such risks and uncertainties may include, but are not limited to, the risks and uncertainties set forth in the Company's filings with the SEC, such as the ability to obtain additional financing, the effect of economic and business conditions, the ability to attract and retain skilled personnel and factors outside the control of the Company. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the SEC. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities of the Company nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Contacts: Artepharm Global Corp. 604-575-3552 604-575-3559 (FAX) info@artepharmglobal.com www.artepharmglobal.com